BioLife Solutions, Inc. (BLFS)
Market Cap | 1.04B |
Revenue (ttm) | 154.81M |
Net Income (ttm) | -103.83M |
Shares Out | 42.77M |
EPS (ttm) | -2.48 |
PE Ratio | n/a |
Forward PE | 625.00 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 266,115 |
Open | 25.82 |
Previous Close | 26.02 |
Day's Range | 23.75 - 26.30 |
52-Week Range | 10.40 - 29.92 |
Beta | 1.81 |
Analysts | Buy |
Price Target | 31.62 (+29.43%) |
Earnings Date | Feb 27, 2023 |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is $31.62, which is an increase of 29.43% from the latest price.
News

BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences
BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance
Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue grow...

BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023
Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL,...

BioLife Solutions Expands Intellectual Property Estate
7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash. , Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: B...

BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report
Only 60 Companies Selected – Based on 2,000 Respondents BOTHELL, Wash. , Nov. 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supp...

BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...

BioLife Solutions Reports Third Quarter 2022 Financial Results
Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow from ...

BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022
BOTHELL, Wash. , Nov. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and ...

CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market
CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash. , Oct. 11, 2022 /PRNewswire/ -- CSafe, one o...

BioLife Solutions Announces COO to Retire and Join Board of Directors
Roderick de Greef retirement planned for January 2023 with appointment to BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior Vice Presiden...

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors
Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash. , Aug. 25, 2022 /PRNewswire/ -- BioL...

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance
Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to $160 million to $166 mi...

BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022
BOTHELL, Wash., Aug. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...

BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services
The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level BOTHELL, Wash. , June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc.

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions Reports First Quarter 2022 Financial Results
Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 milli...

BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services
BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...

BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022
BOTHELL, Wash. , May 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...
New Strong Sell Stocks for May 2nd
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022

BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP
BOTHELL, Wash. , April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

New Strong Sell Stocks for March 31st
BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.

BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing
BOTHELL, Wash. , March 18, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servi...

BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K
BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market
BOTHELL, Wash. , March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an...